NCT00183820

Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma

A Phase II Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: University of Southern California · Academic / Other
• Sex: Male
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

This is a study for patients with advanced testicular cancer. This research study involves treatment with oxaliplatin, paclitaxel, and gemcitabine, which is an investigational chemotherapy combination. This study is for patients who have not responded to standard cisplatin-containing chemotherapy or the cancer has returned after such treatment. This research is being done to assess the effectiveness of the proposed combination of medications for this type of cancer.

Conditions

• Testicular Cancer
• Germ Cell Neoplasm

Interventions

Type	Name	Description
DRUG	paclitaxel, gemcitabine, and oxaliplatin	1. Paclitaxel 170 mg/m2 IV d 1 14 days 2. Gemcitabine 800 mg/m2 IV d 1 14 days 3. Oxaliplatin 100 mg/m2 IV d 1 14 days

Timeline

• Start date: 2004-11-01
• Primary completion: 2015-12-01
• Completion: 2016-08-01
• First posted: 2005-09-16
• Last updated: 2017-07-07

Locations

1 site across 1 country: United States